Aytu BioPharma enters amended employment agreements with CEO Josh Disbrow and CFO Mark Oki

AYTU BIOPHARMA, INC

CEO Disbrow’s agreement amended to one-year terms with auto-renewal; change of control acceleration requires termination within 12 months.
CFO Oki’s agreement modified to conform equity acceleration and Cause definition changes including willful malfeasance standard.
Cause definitions revised across both agreements: willful malfeasance/willful misconduct replaces material misconduct and gross negligence.
Both amendments supersede prior employment agreements; terms approved by Compensation Committee.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.